SomnoMed Co-CEO Amrita Blickstead resigns
· Amrita Blickstead has stepped down as Co-CEO of SomnoMed, leaving Karen Borg as sole CEO.
· Following the announcement, SomnoMed shares were down at $0.47.
· The leadership transition accompanies the company's global expansion and the product launch of its Virtus oral appliance.
Medical device maker SomnoMed (ASX:SOM) announced Co-CEO Amrita Blickstead stepped down on July 27, leaving Karen Borg to lead the business globally.
Borg served alongside Blickstead as co-CEO since February 2024 before assuming complete executive leadership of the company.
“Our daily collaboration was central to the turnaround of the company and has enabled a solid foundation for its future,” said SomnoMed Co-CEO Karen Borg.
During Blickstead's six-year total tenure with the company, SomnoMed passed the milestone of treating over 1 million patients across more than 20 countries.
Following the announcement, the SomnoMed share price was down at $0.47.
The company focuses on providing oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnoea.
SomnoMed stated that recent management efforts focused on improving financial performance, accelerating turnaround times, and increasing manufacturing capacity for its global market expansion.
